30 results about "Kidney Replacement Therapy" patented technology

A method and device for blood treatments that use fluids such as dialysate and replacement fluid for renal replacement therapy. In an embodiment, fluid is passed either by pump or passively by gravity feed, through a microporous sterilization filter from a fluid source to a replacement fluid container. The latter forms a batch that may be used during treatment. The advantage of forming the batch before treatment is that the rate of filtering needn't match the rate of consumption during treatment. As a result, the sterilization filter can have a small capacity. In another embodiment, a filter is placed immediately prior to the point at which the sterile fluid is consumed by the treatment process. The latter may be used in combination with the former embodiment as a last-chance guarantee of sterility and / or that the fluid is free of air bubbles. It may also be used as the primary means of sterile-filtration.

Systems and methods for the performance of kidney replacement therapy having or using a dialyzer, control components, sorbent cartridge and fluid reservoirs configured to be of a weight and size suitable to be worn or carried by an individual requiring treatment are disclosed. The system for performing kidney replacement therapy has a controlled compliance dialysis circuit, where a control pump controls the bi-directional movement of fluid across a dialysis membrane. The dialysis circuit and an extracorporeal circuit for circulating blood are in fluid communication through the dialysis membrane. The flux of fluid moving between the extracorporeal circuit and the dialysis circuit is modified by the rate at which the control pump is operating such that a rate of ultrafiltration and convective clearance can be controlled. The system provides for the monitoring of an inlet and outlet conductivity of the sorbent cartridge to provide a facility to quantify or monitor the removal of urea by the sorbent cartridge.

A multichannel infusion system for use with a hemofilter includes first and second measurement devices that measure the weight of a replacement fluid in a first receptacle and an ultrafiltrate in a second receptacle, a first pumping module configured to accept a first desired flow rate and deliver the replacement fluid from the first receptacle to the hemofilter at the accepted first desired flow rate, a second pumping module configured to accept a second desired flow rate and remove the ultrafiltrate from the hemofilter to the second receptacle at the accepted second desired flow rate, and a control system in communication with the first and second measurement units and the first and second pumping modules. The control system is configured to adjust the first and second desired flow rates based on the measurements made by the first and second measurement devices.

A cardiorenal patient monitoring system comprising, either implanted or non-implanted device(s), remote peripheral device(s), computer network(s), host, and communication means between the device(s), computer network(s), and host. The preferred embodiment shows an advanced patient monitoring system for using an implanted cardiac device and a dialysis machine in renal therapy. In addition, the method of advanced patient monitoring is in conjunction with the advanced patient monitoring system is disclosed.

A method as well as an apparatus is disclosed for determining the efficiency of a currently performed kidney replacement therapy on the dialysis side making use of a dialysis machine which in a first step is operated in a hemodialysis or hemodiafiltration process and in a second step is sequentially changed over to a hemofiltration process or is changed over to a sequential mode in which merely a flow from the blood compartment via the semipermeable membrane to the dialysis fluid compartment of the dialyser is generated in which, according to a third step, a sensor for determining or measuring the concentration at least of uremic toxins in the saturated dialysate or ultra-filtrate which is connected downstream of a dialyser on the dialysis side outputs corresponding measuring signals that are representative of the current concentration at least of uremic toxins in the blood to a calculation or determination unit.

The present invention provides methods for the treatment, and pharmaceuticals for use in the treatment, of mammalian subjects in, or at risk of chronic renal failure, or at risk of a need for renal replacement therapy. The methods involve the administration of certain proteins of, or based upon, the osteogenic protein / bone morphogenetic protein (OP / BMP) family within the TGF-β superfamily of proteins.

The invention relates to a medicament containing an effector of the glutathione metabolism together with alpha -lipoic acid, its salts and / or prodrugs as a combined preparation for the simultaneous, separate or time-controlled treatment of a defective thiol-disulfide status in kidney replacement therapy and of clinical characteristics, which indicate a disorder of the thiol-disulfide status of immunocytes. The correction of a defective thiol metabolism is of fundamental importance as a basic therapy for treating a large number of diseases of different origin, in particular however in circumstances requiring an essential kidney replacement therapy.

A fluid extraction or filtration device for removing fluid from a body, the device comprising an array of microneedles for contacting fluid in said body and an absorbent gel matrix in fluid communication with said array of microneedles. There is further provided a combined fluid extraction and sampling device and methods employing the device(s), for example in determining the level of a target species in a sample of fluid, transdermal dialysis and renal replacement therapy. There is further provided an absorbent gel matrix for use in the treatment of uraemia and a haemodialysis filter comprising an absorbent gel matrix. Use of such a matrix is described in the context of methods including haemodialysis, transdermal dialysis and gastrointestinal dialysis.

Apparatuses, systems, and methods for the performance of kidney replacement therapy having or using a dialyzer, control components, sorbent cartridge, and fluid reservoirs configured to be of a weight and size suitable to be worn or carried by an individual requiring treatment are disclosed. The system has a controlled compliance dialysis circuit, where a control pump controls the bi-directional movement of fluid across a dialysis membrane. A first sorbent cartridge is provided for use in a portable treatment module having activated carbon and zirconium oxide. The system also provides for the monitoring of an inlet and outlet conductivity of a sorbent cartridge containing urease to provide a facility to quantify or monitor the removal of urea by a detachable urea removal module.

The invention discloses application of danshinolic acid components in preparing pharmaceutical preparations for improving the dialysis rate and filtration rate of protein-bound uremic toxins. The danshinolic acid components include danshinolic acid B, protocatechuic aldehyde, rosmarinic acid, other danshinolic acid monomer components, pharmaceutical preparations containing salviae miltiorrhizae, pharmaceutical preparations containing salviae miltiorrhizae and safflower, and medicine suits with different salviae miltiorrhizae and safflower compatibility proportions. Through screening of a lot of experiments, results show that salviae miltiorrhizae and safflower injections and the danshinolic acid components can remarkably improve the dialysis efficiency of the protein-bound uremic toxins, can remarkably improve the filtering efficiency of the protein-bound uremic toxins, can be developed into auxiliary medicine preparations of in-vitro kidney replacement therapy strategies such as kidney disease dialysis and blood filtering, and have good development and application prospects.

The present disclosure relates to the use of alkaline phosphatases, and in particular improved alkaline phosphatases such as RecAP, for the prevention, treatment, cure, or amelioration of the symptomsof acute kidney injury caused, e.g., by sepsis. The application relates to methods of preserving renal function renal function, shortening the duration of renal replacement therapy, increasing the creatinine clearance, decreasing the risk of death in subjects with sepsis-associate acute kidney injury (SA-AKI) or at risk of SA-AKI.

The present invention provides methods for the treatment, and pharmaceuticals for use in the treatment, of mammalian subjects in, or at risk of chronic renal failure, or at risk of a need for renal replacement therapy. The methods involve the administration of certain integrin antagonists.

The invention discloses an intermittent CRRT (Continuous Renal Replacement Therapy) machine capacity balance device. The device comprises a blood circulation system, a first liquid circulation system, and a second liquid circulation system, wherein the blood circulation system consists of a hollow fiber dialyzer, a liquid outlet pipeline, a first circuit interrupting device, a liquid pump, a displacement liquid / dialysis liquid container and a liquid return pipeline; the second liquid circulation system consists of an exogenous displacement liquid / dialysis liquid container, an exogenous displacement liquid / dialysis liquid container liquid outlet pipeline, a second circuit interrupting device, a liquid pump, a displacement liquid / dialysis liquid container, and an exogenous displacement liquid / dialysis liquid container liquid return pipeline; the first liquid circulation system is in contact with the blood circulation system to perform substance exchange; since the volumes are fixed, volume change is not involved in the process of exchange; the first liquid circulation system is separated from the blood system, and is connected to the second liquid system to perform liquid exchange to be refilled with clean fresh displacement liquid, and then performs solute exchange with the blood system. The process is repeated to fulfill the aim of continuously removing solute.

A method for predicting a need for Renal Replacement Therapy (RRT) in a patient comprises: determining a concentration of pi glutathione S transferase-(πGST) in a first urine sample from the patient; and wherein a need for RRT is predicted when the πGST concentration is determined to be elevated in comparison to a patient without kidney injury. The method according to the invention can further comprise detecting for the presence of risk factors for RRT in a patient, the risk factors including elevated serum creatinine concentration, type I diabetes, type II diabetes, hypertension, dyslipidemia, hyperglycaemia, proteinuria and hypoalbuminemia.